*The following content is generated by AI and is for reference only.
<h3>Overview</h3>
<p>A fixed-dose combination regimen for HIV-1 treatment. It integrates <strong>Lamivudine</strong> (CAS 134678-17-4), <strong>Tenofovir Disoproxil Fumarate</strong> (CAS 205159-90-8), and <strong>Nevirapine</strong> (CAS 129612-86-2). The co-packaging ensures synchronized dosing to optimize adherence and viral suppression.</p>
<h3>Application</h3>
<ul>
<li>HIV-1 antiretroviral therapy in adults and pediatric patients.</li>
<li>First-line treatment protocols in resource-limited settings.</li>
<li>Post-exposure prophylaxis under strict medical supervision.</li>
</ul>
<h3>Precautions</h3>
<p>Contraindicated in severe hepatic impairment or hypersensitivity. Monitor for lactic acidosis, hepatotoxicity, and opportunistic infections. Store below 25°C in a dry environment away from direct light.</p>